 MINNEAPOLIS, June 14, 2021 GLOBE NEWSWIRE -- Predictive Oncology Inc. NASDAQ: POAI Predictive Oncology or the Company, a knowledge-driven company focused on applying artificial intelligence AI to personalized medicine and drug discovery, today announced that it has entered into definitive agreements with several institutional investors for the issuance and sale of an aggregate of 15,520,911 shares of its common stock and warrants to purchase up to an aggregate of 15,520,911 shares of its common stock at a purchase price of 1.375 per share of common stock and related warrant in a registered direct offering priced at-the-market under Nasdaq rules. The warrants have an exercise price of 1.25 per share, will become exercisable upon the Company increasing its authorized capital stock to 200 million shares, and will expire three 3 years following the date the warrants first become exercisable. The closing of the offering is expected to occur on or about June 15, 2021, subject to the satisfaction of customary closing conditions. 